Intuitive Surgical Inc
Exchange: NASDAQSector: HealthcareIndustry: Medical Instruments & Supplies
Intuitive, headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. About da Vinci Surgical Systems There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. About the Ion Endoluminal System The Ion Endoluminal System (Model IF1000) assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use. Information provided by the Ion Endoluminal System or its components should be considered guidance only and not replace clinical decisions made by a trained physician.
Did you know?
A large-cap company with a $166.0B market cap.
Current Price
$468.36
+0.24%GoodMoat Value
$225.00
52.0% overvaluedProfile
Valuation (TTM)
Market Cap$166.03B
P/E58.13
EV$163.53B
P/B9.32
Shares Out354.50M
P/Sales16.50
Revenue$10.06B
EV/EBITDA40.35
Intuitive Surgical Inc (ISRG) Stock Analysis
GoodMoat Analysis
Intuitive Surgical is a high-quality business with a strong competitive moat in robotic-assisted surgery, but its current valuation appears extremely demanding. The stock's price is more than double the GoodMoat target, suggesting a significant overvaluation. This combination of a strong business at an unfavourable price makes it a candidate for further investigation only with extreme caution.
Read full analysis
Intuitive Surgical designs, manufactures, and markets the da Vinci surgical system, a robotic platform for minimally invasive surgery. Its competitive moat is formidable, likely scoring high on the framework's criteria. It benefits from powerful switching costs, as hospitals invest heavily in surgeon training and system integration. It holds technology leadership through foundational patents and a massive installed base, creating a virtuous cycle of procedural data that improves its systems. The company also exhibits strong pricing power as the dominant, mission-critical provider in its niche. Financially, it shows high-quality indicators with a 28.4% profit margin, 18.8% revenue growth, and a 16.0% ROE. Applying the Decision Framework, the business passes the Moat & Quality Gate with ease. However, it fails the Valuation & Risk Gate. The current P/E of 58.3 is extremely high, and the stock price of $469.98 is more than 100% above the GoodMoat target of $225. This suggests a deeply unfavourable or negative margin of safety in a DCF analysis. While the underlying business is excellent, the valuation presents a severe caution signal, placing the stock in the 'With Caution' or 'Unfavourable' category for a value investor seeking a margin of safety. Analysis based on data as of 2024-05-15.
Market Cap$166.03B
Current Price$468.36
P/E Ratio58.13
Forward P/E—
PEG Ratio3.74
EPS$7.87
Book Value$50.28
P/B Ratio9.32
ISRG Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 13.4% FCF growth (CAGR)
Cash vs Debt
Net Cash: 3.4B
Revenue
4.5B
FY19
4.4B
FY20
5.7B
FY21
6.2B
FY22
7.1B
FY23
8.4B
FY24
10.1B
FY25
Net Income
1.4B
FY19
1.1B
FY20
1.7B
FY21
1.3B
FY22
1.8B
FY23
2.3B
FY24
2.9B
FY25
ISRG 52-Week Range
$429.59
$592.85
50-Day MA: $480.35200-Day MA: $503.86
Did you know?
Profit margin of 28.4% — that's well above average.
Intuitive Surgical Inc (ISRG) Financial Summary
Intuitive Surgical Inc (ISRG) is a Healthcare company in the Medical Instruments & Supplies industry, listed on NASDAQ. The stock currently trades at $468.36 with a market capitalization of $166.03B.
Key valuation metrics include a P/E ratio of 58.13, price-to-book ratio of 9.32, and EPS of $7.87. The company reports a profit margin of 28.4% and return on equity of 16.0%.
ISRG Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $166.03B |
| P/E Ratio | 58.13 |
| EPS | $7.87 |
| P/B Ratio | 9.32 |
| P/S Ratio | 16.50 |
| EV/EBITDA | 40.35 |
| Profit Margin | 28.4% |
| Return on Equity | 16.0% |
ISRG Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $4.48B | $1.38B |
| FY20 | $4.36B | $1.06B |
| FY21 | $5.71B | $1.70B |
| FY22 | $6.22B | $1.32B |
| FY23 | $7.12B | $1.80B |
| FY24 | $8.35B | $2.32B |
| FY25 | $10.06B | $2.86B |
Intuitive Surgical Inc (ISRG) Valuation
Based on GoodMoat's DCF model, Intuitive Surgical Inc has a fair value estimate of $225.00. At the current price of $468.36, the stock appears 108.2% overvalued relative to our intrinsic value estimate.
ISRG Quality Indicators
Intuitive Surgical Inc maintains a profit margin of 28.4% and an operating margin of 29.3%. Return on equity stands at 16.0%. The current ratio is 4.87.
About Intuitive Surgical Inc
Intuitive, headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most. About da Vinci Surgical Systems There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body. About the Ion Endoluminal System The Ion Endoluminal System (Model IF1000) assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use. Information provided by the Ion Endoluminal System or its components should be considered guidance only and not replace clinical decisions made by a trained physician.
ISRG Free Cash Flow
Intuitive Surgical Inc generated $2.49B in trailing twelve-month free cash flow, representing an FCF yield of 1.50%. This low FCF yield may reflect heavy reinvestment or growth spending.
ISRG Shares Outstanding
Intuitive Surgical Inc has 0.35 billion shares outstanding at a share price of $468.36, giving it a market capitalization of $166.03B.
ISRG Recent Insider Trades
Recent insider transactions at Intuitive Surgical Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Curet Myriam (EVP & Chief Medical Officer) | SELL | 105 | $51864.75 |
| Brosius Mark (SVP & Chief Mfg and Supply Cha) | SELL | 648 | $317643.12 |
| Brosius Mark (SVP & Chief Mfg and Supply Cha) | SELL | 648 | $316288.80 |